Johnson & Johnson Business Exit Costs (Deprecated 2013-01-31)
Johnson & Johnson (JNJ) reported Business Exit Costs (Deprecated 2013-01-31) of $76.00 million for the 3-month period ending 2010-01-03, per its 10-Q filed 2011-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessExitCosts · last filed 2011-05-10
- Johnson & Johnson business exit costs (deprecated 2013-01-31) for the quarter ending 2010-01-03 was $76.00M.
| Period end | Business Exit Costs (Deprecated 2013-01-31) 3 month |
|---|---|
| 2010-01-03 | $76.00M 10-Q · filed 2011-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |